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ABSTRACT 
Post stroke hyperglycaemia (PSH) is prevalent in acute ischaemic stroke (AIS) patients and it 
has been associated with a dismal outcome of death and disability. Insulin has been proven to 
attenuate glucose effectively in stroke patients, thus many trials over the years had studied the 
efficacy of intensive treatment aiming at normalization of blood sugar level in order to im-
prove the bleak outcomes of PSH. However, tight glycaemic control failed to be translated in-
to clinical benefits and the outcomes are no different from the conventional approach, despite 
the costly healthcare expenditure invested. On the contrary, it brings more significant harm 
than the intended benefit, as 1 in every 9 treated patients had symptomatic hypoglycaemia. 
Thus, the benefits of tight glucose control, if any, are overshadowed by this potential risk of 
hypoglycaemia causing permanent neurological injury. Therefore, international practice 
guidelines recommend for less aggressive treatment to maintain blood glucose level within an 
appropriate range in AIS patients. However, there are limited details for stroke-specific gly-
caemic management and this made management of PSH particularly difficult. This review is 
to discuss and provide suggestions concerning glycaemic control in acute ischaemic stroke; 
the direction of its future prospective clinical trials and the treatment strategy required based 
on recent literature. 
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INTRODUCTION 
Almost 2 in every 3 acute stroke patients 
have elevated blood glucose more than 
6.1 mmol/L at presentation, reflecting the 
alarmingly high prevalence of post stroke 
hyperglcaemia (PSH) in acute ischaemic 
stroke (AIS) populations (Scott et al., 
1999b). In recent years, there has been much 
discussion over the possible mechanisms of 
hyperglycaemia causing ischaemic brain in-
jury. It has been postulated that hypergly-
caemia is associated with impaired recanali-
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zation (Ribo et al., 2005), decreased perfu-
sion (Quast et al., 1997), increased reperfu-
sion injury (Kamada et al., 2007) and cere-
bral lactic acidosis secondary to mitochon-
drial dysfunction (Anderson et al., 1999). 
In AIS, the prognostic influence of gly-
caemia level is evident. Whether PSH is the 
result of uncontrolled diabetes or newly di-
agnosed diabetes, or merely a physiological 
stress response, it is an important independ-
ent prognosticator of stroke mortality in AIS 
patients (Capes et al., 2001; Weir et al., 
1997). These hyperglycaemic stroke patients 
are susceptible to have a larger cerebral in-
farct with subsequent worsening of neuro-
logical disabilities (Parsons et al., 2002). 
Admission hyperglycaemia is found to in-
crease the risk of death by 2.3 times in AIS 
patients (Stead et al., 2009). Likewise, mor-
bidity of AIS patients with persistent hyper-
glycaemia more than 8.5 mmol/L was found 
to be 3 times more than normoglycaemic 
stroke patients (Fuentes et al., 2009).  
In spite of the fact that early and persis-
tent inpatient hyperglycaemia causing poor 
outcome, there is still no consensus on the 
specific management of hyperglycaemia in 
AIS, as opposed to hyperglycaemia in non-
stroke acute illnesses (Quinn et al., 2011). 
The effect of hyperglycaemia to the brain is 
different than peripheral tissues as its glu-
cose metabolism is more complex and the 
energy consumption is higher (Pakhetra et 
al., 2011) Furthermore, the insulin receptors 
in the brain are structurally and functionally 
different from the peripheral receptors, as 
they have insulin-independent means of ob-
taining glucose and the ability to modulate 
neurotransmitter function. Their role in the 
function and development of central nervous 
system (CNS) is more than just regulation of 
glucose utilization (Schulingkamp et al., 
2000). 
In light of the foregoing, this review will 
highlight on the complex relationship be-
tween hyperglycaemia and ischemic stroke, 
addressing controversial issues such as target 
and glycaemic control and its association 
hypoglycaemic complication and monitor-
ing, as well as treatment strategies such as 
route, timing and duration of therapy. 
 
GLUCOSE-LOWERING THERAPY: 
WHAT AND HOW TO START? 
Oral glycaemic control agents are not 
recommended for treatment of PSH due to 
the danger of hypoglycaemia and acidosis 
when used in acutely ill patients, especially 
in dysphagic stroke patients (Baker et al., 
2011). Instead, insulin is the preferred treat-
ment for several reasons. First, the therapeu-
tic efficacy of insulin treatment for PSH is 
proven to reduce the glucose level in AIS pa-
tients (Bellolio et al., 2014; Laird and 
Coates, 2013). Second, intravenous or subcu-
taneous insulin is easier to administer on 
stroke patients, especially those with swal-
lowing difficulties and reduced conscious 
level. Third, insulin also promotes an activity 
of endothelial nitric oxide (Cleland et al., 
2000) and has an immune-modulatory ef-
fects that may control the infarction size 
which subsequently improve the prognosis 
of PSH patients (Marik and Raghavan, 2004; 
Hamilton et al., 1995).  
As compared to subcutaneous insulin re-
gime, intensive intravenous insulin lowers 
blood glucose more significantly in the first 
hours of stroke presentation. However, AIS 
patients treated with intensive insulin thera-
py are 18 times more likely to have hypogly-
caemia (Bellolio et al., 2014). Moreover, hy-
poglycaemia in AIS patients might be more 
harmful than in non-stroke patients as it can 
cause deleterious neurological outcomes (de 
Courten-Myers et al., 1994; Zhu and Auer, 
2004), but the exact glucose value that can 
be considered dangerously low is still unas-
certained (Kruyt et al., 2010). Hence, recent 
American stroke guideline recommends the 
use of subcutaneous insulin, as the risk of 
hypoglycaemia is less. Subcutaneous insulin 
with basal insulin regimes can usually main-
tain appropriate normoglycaemia in most 
AIS patients (Bruno et al., 2010). In addi-
tion, monitoring and administering of meal 
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subcutaneous insulin sliding scale is simpler 
i.e. only four times a day as compared to rig-
orous hourly glucose monitoring for intrave-
nous insulin infusion therapy. A simple 
weight based subcutaneous insulin basal bo-
lus regimens, along with insulin sensitivity 
factor should be used when calculating the 
insulin dosing to achieve better glucose con-
trol (Baker et al., 2011). 
Nevertheless, if the hyperglycaemia is 
persistently more than 11.1 mmol/L, intrave-
nous insulin infusion may be used with fre-
quent glucose monitoring (Jauch et al., 
2013). Since there are several sliding scale 
protocols available, the choice depends on 
familiarity and availability of health re-
sources, and safety in term of appropriate ad-
justments in case of hypoglycaemia events. 
In special circumstances such as type 1 dia-
betes mellitus, diabetic ketoacidosis, hyper-
osmolar state or difficult nutrition regimens, 
an endocrine consultation is necessary for an 
optimum management (Baker et al., 2011). 
Besides hypoglycaemia as the major ad-
verse effects of insulin therapy, hypokalae-
mia can also occur as insulin causes extracel-
lular shift of potassium into the cells (Radó, 
1989). In spite of this, no significant hypoka-
lemia was reported in two trials using intra-
venous insulin (Bruno et al., 2008; Walters 
et al., 2006). The usage of intravenous infu-
sion of glucose-potassium-insulin (GKI) so-
lution is intended to be more physiological in 
reducing the glucose level and maintaining 
potassium level. Several randomised con-
trolled studies that have used GKI in their 
treatment arm found that GKI solution was 
beneficial and safe to be administered to AIS 
patients with mild to moderate PSH, alt-
hough evidence on the clinical gain is not 
significant (McCormick et al., 2010; Scott et 
al., 1999a; Gray et al., 2007). 
In short, the possible options of inpatient 
glucose lowering protocol in PSH are subcu-
taneous insulin or intravenous insulin or GKI 
infusion solution. It depends on the severity 
of hyperglycaemia, the risk of hypoglycae-
mia and the availability of labour and 
healthcare resources. Regular monitoring of 
the blood glucose and electrolytes is essen-
tial in order to avoid the complication of hy-
poglycaemia and hypokalemia from insulin 
therapy. 
 
WHEN TO START TREATMENT? 
The current recommendation of interna-
tional guidelines regarding ischaemic stroke 
patients, is blood glucose should be main-
tained within the normoglycaemic range 
(Baker et al., 2011; Jauch et al., 2013; Inter-
collegiate Stroke Working Party 2012). But 
the exact glucose value by which insulin 
treatment should be initiated is unclear, since 
different studies used different cut-off values 
of hyperglycaemia. 
Data analysed from the Virtual Interna-
tional Stroke Trials Archive (VISTA) (Ali et 
al., 2007), an established central stroke da-
tabase, reported a 12.9 % increase in mortal-
ity and poor functional outcome among stro-
ke patients with glucose levels of more than 
7 mmol/L for 48 hours (Muir et al., 2011). 
The Glycemia in Acute Stroke study (GLI-
AS) and also large scale study done on 960 
AIS patients showed similar poorer outcome 
in stroke patients with higher cut-off glucose 
value i.e. 8.6 mmol/L and 8.2 mmol/L re-
spectively (Gentile et al., 2006; Fuentes et 
al., 2009). 
It is still unclear when to start insulin 
treatment during PSH, though early initiation 
time may be beneficial. In a study on PSH 
patients with normalization of glucose dur-
ing initial 48 hours of admission, the risk of 
death is reduced by 4.6 times compared to 
those with persistent hyperglycemia 
(Dziedzic et al., 2010). A study from VISTA 
databases showed those AIS patients who re-
ceived insulin treatment at a median 5.5 h af-
ter admission had a better prognosis at 90 
days (Muir et al., 2011). In addition, the 
practicability and safety of rapid corrections 
of hyperglycaemia with intravenous insulin 
during AIS has also been shown in other 
clinical trials (Bruno et al., 2008; Johnston, 
et al., 2009; Kreisel et al., 2009). Nonethe-
EXCLI Journal 2014;13:825-833 – ISSN 1611-2156 
Received: June 06, 2014, accepted: July 03, 2014, published: August 13, 2014 
 
 
828 
less, in hyper-acute stroke presentation (< 6 
hours), intensive intravenous insulin should 
be used with caution as a study had linked it 
with infarct growths (Rosso et al., 2012). 
In summary, the definitive timing and 
glucose value at which insulin treatment 
should be initiated remain to be determined, 
although earlier initiation from the first 24 to 
48 hours after admission is practical and may 
be beneficial (Jauch et al., 2013; Baker et al., 
2011). 
 
DURATION OF TREATMENT: 
24, 48, 72 HOURS OR > 5 DAYS? 
In relation to the duration of insulin ther-
apy, no guidelines are available. For subcu-
taneous insulin regimens, the ideal practice 
is to continue the inpatient treatment to out-
patient care, with a reduction of 10 to 20 % 
dosage to prevent hypoglycaemia. As for in-
travenous insulin infusion, different trials of 
acute glycaemic intervention in PSH used 
different durations of treatment, ranging 
from 1 to 5 days. 
A study by Walters MR et al. (2006) 
found 48 hours duration of insulin infusion 
was sufficient and treatment more than 48 
hours was unnecessary. In addition, VISTA 
and GLIAS study found that hyperglycaemia 
within initial 48 hours was associated with 
higher mortality (Fuentes et al., 2009; Muir 
et al., 2011). On the contrary, shorter 24-
hour insulin duration as in GIST-UK study 
did not show any significant clinical impact.  
In regard to hypoglycaemia risk, there 
was no association between longer duration 
of treatment and hypoglycaemia. For in-
stance, GRASP which has 5 days duration of 
treatment as compared to THIS trial, with a 
24-hour duration of treatment, had similar 
incidence of hypoglycaemia in the intensive 
insulin treatment group. Therefore, even a 
short duration of insulin treatment can result 
in hypoglycaemia, with rate as high as 71 % 
(Kim et al., 2009). 
To conclude, 48 hours of intravenous 
insulin treatment appears to be the optimal 
duration and should be used as the interven-
tion duration in future trials.  
 
GLUCOSE LEVEL:  
WHAT LEVEL TO ACHIEVE? 
International practice guidelines recom-
mend for less aggressive insulin treatment to 
maintain blood glucose level within an ap-
propriate range in AIS patients. However 
few recommendations are provided for 
stroke-specific glycaemic management and 
this made management of PSH complicated. 
The aggressiveness of glucose management 
control in stroke patients varies according to 
physician specialty groups (Casaubon et al., 
2008). 
The recently updated Cochrane systemat-
ic review in 2014 had analysed 11 random-
ised controlled trials (RCT) of insulin treat-
ment for PSH in diabetics and non diabetics 
patients, with narrow target blood glucose of 
4 to 7.5 mmol/L, looking at dependency or 
death at 1 month or 3 month as the primary 
outcome (Bellolio et al., 2014). The review 
had updated 3 new RCTs but the results are 
unchanged from the previous first review in 
2011 (Bellolio et al., 2011). Again, it con-
cluded that tight glycaemic control failed to 
be translated into clinical benefits, as the 
outcomes are no different than conventional 
approach, despite the costly healthcare re-
sources invested. In fact, it brings more sig-
nificant harm than the intended benefit, as 1 
in every 9 treated patients had symptomatic 
hypoglycaemia. The possible benefits of 
controlling tight glucose levels, if any, are 
overshadowed by this potential risk of hypo-
glycaemia causing permanent neurological 
injury.  
For this reason, AHA/ASA 2013 guide-
lines suggested that it is practical to treat 
PSH by maintaining blood glucose levels in 
a range of 7.8 to 10.0 mmol/L in all hospital-
ized patients (Jauch et al., 2013). European 
stroke 2012 guidelines also has a similar 
suggestion but with a broader range of 4 to 
11 mmol/L target blood glucose (Intercolle-
giate Stroke Working Party, 2012). 
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Until further clinical trials establish the 
efficacy and the risk-benefit ratio of rapid 
hyperglycemia correction during AIS, a 
loose glycaemic target should be encouraged 
in order to avoid hypoglycemia and exces-
sive resource that is associated with its pre-
vention and monitoring in PSH. Perhaps the 
current much anticipated on-going SHINE 
trial will provide a clear lead to this contro-
versial PSH management (Bruno et al., 
2014). 
 
MORE ABOUT HYPOGLYCAEMIA 
Hypoglycaemia in stroke patients most 
commonly occurs when glucose lowering 
treatment is instituted and rarely occurs 
spontaneously. There are no unified defini-
tions of hypoglycaemia in AIS (Bruno et al., 
2008; Gray et al., 2007), though in practice, 
the diagnosis of hypoglycaemia is usually by 
the Whipple’s triad (Cryer et al., 2009). 
Since the clinical manifestations are some-
times non specific (McAulay et al., 2001), 
documentation of abnormally low blood glu-
cose with the event of hypoglycaemia is val-
uable in diagnosis (Baker et al., 1997). Ame-
rican Diabetes Association proposes cut-off 
values of less than 3.9 mmol/L and further 
classification depends on the glycaemia val-
ues and its associated symptoms (American 
Diabetes Association Workgroup on Hypo-
glycemia, 2005). Low glycaemic values of 
2.8 to 3.9 mmol/L are typically considered 
mild hypoglycaemia if patients are asymp-
tomatic and moderate hypoglycaemia if pa-
tients have autonomic symptoms such as 
tremors and sweating. Lower glycaemic val-
ues less than 2.2 to 2.8 mmol/L with neuro-
logical dysfunction symptoms are regarded 
as severe hypoglycaemia (Baker et al., 2011; 
Cryer et al., 2003). However, in patients with 
diabetes, the threshold value for glucose lev-
el of symptomatic hypoglycaemia is higher 
(3.9 mmol/L) than in non-diabetes patients 
(3.0 mmol/L) (Desouza et al., 2010; Cryer et 
al., 2009). This is an important factor, as 
most studies on tight glycaemic control in 
AIS, did not consider whether the hypogly-
cemia is harmful to the patients or not.  
Different studies used different cut-off 
values ranging from < 3.0 to < 4.0 mmol/L, 
but the recent Cochrane systematic review 
uses glucose level less than 3.0 mmol/L and 
the patients are further classified into symp-
tomatic or asymptomatic hypoglycaemia 
(Bellolio et al., 2014). The chosen cut-off 
point will have a significant impact on the 
number of reported cases of hypoglycaemia. 
Therefore, for future studies that includes di-
abetic stroke patients, standardised definition 
of hypoglycaemia is needed and should be 
set lower than the definition of 3.9 mmol/L 
(Swinnen et al., 2009).  
Proper management of hypoglycaemia is 
crucial as prolonged untreated hypoglycae-
mia can result in permanent neurological in-
jury and even death. Once hypoglycaemia is 
identified in AIS patient, it should be treated 
urgently with dextrose solution, preferably 
25 mL of 50 % dextrose given in slow intra-
venous push (Jauch et al., 2013). 
 
FUTURE TRIALS 
Several factors need to be taken into ac-
count when initiating future clinical trials. 
First, most studies in this review that includ-
ed both diabetic and non-diabetic AIS pa-
tients, revealed conflicting mortality out-
comes between them. A large meta-analysis 
of 32 cohort studies concluded that in PSH, 
non diabetic patients have worse mortality 
and functional outcome than diabetic pa-
tients (Capes et al., 2001). A lower value of 
cut-off glucose level of 6.3 mmol/L in non-
diabetic patients is associated with early fa-
tality, as compared to 10.3 mmol/L in diabet-
ic patients, according to another study 
(Farrokhnia et al., 2005). In terms of inten-
sive treatment with intravenous insulin, on 
the contrary, a systematic review of 11 stud-
ies found no difference in outcome between 
patients with diabetes mellitus and without 
diabetes mellitus (Bellolio et al., 2014). 
Second, all studies did not differentiate 
between lacunar and cortical stroke in their 
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inclusion criteria and this may attribute to 
conflicting result. Initial studies in animals 
with lacunar infarcts had reported beneficial 
effect of hyperglycaemia and aggressive 
treatment (< 7 mmol/L) was proven harmful 
(Ginsberg et al., 1987; Prado et al., 1988). 
Likewise, a recent clinical study done on 
1375 ischaemic stroke patients also found 
that moderate PSH of 8.0 to 10.0 mmol/L in 
lacunar infarct resulted in favourable out-
come, independent of stroke severity, diabe-
tes and age (Uyttenboogaart et al., 2007).  
Third, post-hoc analysis of GRASP study 
did show the probability of good functional 
outcome with five days of tight glycaemic 
control of 3.9 to 6.0 mmol/L with insulin 
treatment (Johnston et al., 2009). The shorter 
24 hours to 48 hours duration of treatment 
used in most clinical trials probably is not 
sufficient to improve outcomes as the clini-
cal benefit of glucose lowering therapy is 
probably maximized when treatment is con-
tinued for at least 2 to 3 days beyond the 
acute initial 24 hour stroke presentation 
(Kruyt et al., 2010).  
Hence for future clinical trials, it is rec-
ommended that firstly, longer duration of 
glycaemic control be required to assess the 
efficacy of insulin treatment. Secondly, 
comparison of PSH outcomes between early 
and late insulin intervention with the effect 
of time to euglycaemia should be considered. 
Lastly, selecting non-diabetic patients and 
non-lacunar infarct might enhance the 
chances of finding a treatment effect for gly-
caemic control in PSH. 
 
CONCLUSION 
The management of hyperglycaemia in 
acute stroke should evolve towards less rig-
orous glycaemic control, as compared to the 
previous practice of tight glycaemic control. 
In spite of the numerous studies done, evi-
dence is still inadequate to determine the ju-
dicious hyperglycemia management practice 
in AIS setting. At present, there is no conclu-
sive clinical evidence that tight glycaemic 
control during acute ischemic stroke is the 
right approach, as it does not elude the pos-
sibility of death or disability.  
While we wait for findings from current 
and future clinical researches, the recom-
mended approach in the management of PSH 
is to balance the therapeutic benefit of insu-
lin treatment with the potential harm of hy-
poglycaemia. Taking into consideration the 
manpower, expense and risk involved in a 
timely and safe correction of hyperglycaemia 
in AIS, less aggressive treatment with subcu-
taneous insulin is recommended to ensure 
optimal outcomes. 
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